ATM and neoplasm: This study focuses on the mechanism by which Poly ADP‐Ribose Polymerase inhibitors reverse Homologous Recombination‐Deficient tumor resistance through “synthetic lethality” effects while also revealing the synergistic anti‐tumor effects of ATM/ATR inhibitors in combination with chemotherapeutic agents.